# Surgical approaches to fertility preservation in the cancer patient: current and future directions

**Authors:** Ariella Yazdani, Cara J. Schachter, Elliott G. Richards, Tommaso Falcone

PMC · DOI: 10.3389/fendo.2026.1755050 · Frontiers in Endocrinology · 2026-02-16

## TL;DR

This paper reviews surgical methods to preserve fertility in cancer patients, focusing on the ovary, uterus, and cervix.

## Contribution

The paper provides an updated overview of current and emerging surgical fertility preservation techniques in oncology.

## Key findings

- Ovarian transposition and tissue cryopreservation are effective for preserving ovarian function.
- Uterine transposition and transplantation show promise for preserving reproductive and endocrine function.
- Fertility-sparing cervical procedures maintain oncologic outcomes while preserving reproductive potential.

## Abstract

Advances in oncologic therapies have markedly improved survival among reproductive-age female patients, making fertility preservation an essential component of comprehensive cancer care. Gonadotoxic treatments, including chemotherapy, radiotherapy, and surgery, can disrupt ovarian and uterine endocrine function, resulting in premature ovarian insufficiency and infertility. This narrative review summarizes current and emerging surgical approaches to fertility preservation, organized by anatomic focus on the ovary, uterus, and cervix. Ovarian transposition preserves ovarian endocrine function by relocating the ovaries outside the pelvic radiation field, while ovarian tissue cryopreservation preserves primordial follicles through surgical harvesting, cryostorage, and reimplantation to restore ovarian function and fertility. Emerging uterine-preserving strategies, such as uterine transposition and uterine transplantation, demonstrate growing feasibility for restoring reproductive and endocrine uterine function. Fertility-sparing cervical procedures, including radical and simple trachelectomy, maintain favorable oncologic outcomes while preserving reproductive potential in appropriately selected patients. Across all modalities, multidisciplinary collaboration and individualized counseling are critical to optimize both oncologic and reproductive outcomes. Continued research aimed at refining surgical techniques, improve graft viability, and expanding equitable access will be key to advancing fertility preservation as a standard component of comprehensive cancer care.

## Full-text entities

- **Genes:** TSC1 (TSC complex subunit 1) [NCBI Gene 7248] {aka LAM, TSC}, GDF9 (growth differentiation factor 9) [NCBI Gene 2661] {aka POF14}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, FOXO3 (forkhead box O3) [NCBI Gene 2309] {aka AF6q21, FKHRL1, FKHRL1P2, FOXO2, FOXO3A}, KITLG (KIT ligand) [NCBI Gene 4254] {aka DCUA, DFNA69, FPH2, FPHH, KL-1, Kitl}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, AMH (anti-Mullerian hormone) [NCBI Gene 268] {aka MIF, MIS}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TOP2A (DNA topoisomerase II alpha) [NCBI Gene 7153] {aka TOP2, TOP2alpha, TOPIIA, TP2A}, BMP15 (bone morphogenetic protein 15) [NCBI Gene 9210] {aka GDF9B, ODG2, POF4}, GNRH1 (gonadotropin releasing hormone 1) [NCBI Gene 2796] {aka GNRH, GRH, LHRH, LNRH}
- **Diseases:** ovarian cancers (MESH:D010051), miscarriage (MESH:D000022), breast cancer (MESH:D001943), uterine loss or dysfunction (MESH:D014591), lymphoma (MESH:D008223), pelvic sarcomas (MESH:D034161), empty follicle syndrome (MESH:D004652), stage IA2-IB1 squamous or adenocarcinoma (MESH:D002294), gonadotoxic damage (MESH:D020263), effects on gonadal function (MESH:D006058), amenorrhea (MESH:D000568), hematologic malignancies (MESH:D019337), neuroblastoma (MESH:D009447), OTT (MESH:D010049), ischemia (MESH:D007511), leukemia (MESH:D007938), colorectal cancer (MESH:D015179), mitochondrial damage (MESH:D028361), ovarian failure (MESH:C564499), adhesions (MESH:D000267), immunodeficient (MESH:D007153), cervical cancer (MESH:D002583), melanoma (MESH:D008545), fibrosis (MESH:D005355), metastases (MESH:D009362), disease (MESH:D004194), POI (MESH:D016649), ovarian cyst (MESH:D010048), small bowel obstruction (MESH:D007409), rectal cancer (MESH:D012004), vascular damage (MESH:D057772), cytotoxic (MESH:D064420), abdominal pain (MESH:D015746), CNS tumors (MESH:D016543), ischemic (MESH:D002545), rectal adenocarcinoma (MESH:D000230), Cancer (MESH:D009369), infertility (MESH:D007246), preterm birth (MESH:D047928), gynecologic malignancies (MESH:D005833), myxoid low grade liposarcoma (MESH:D018208), multiple myeloma (MESH:D009101), hernia (MESH:D006547)
- **Chemicals:** cyclophosphamide (MESH:D003520), progesterone (MESH:D011374), cellulose (MESH:D002482), Doxorubicin (MESH:D004317), temsirolimus (MESH:C401859), OTC (-), platinum (MESH:D010984), cisplatin (MESH:D002945), vinca alkaloids (MESH:D014748), vincristine (MESH:D014750)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12950600/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12950600/full.md

## References

105 references — full list in the complete paper: https://tomesphere.com/paper/PMC12950600/full.md

---
Source: https://tomesphere.com/paper/PMC12950600